Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy

Front Immunol. 2021 Aug 3:12:696268. doi: 10.3389/fimmu.2021.696268. eCollection 2021.

Abstract

Context: Disseminated infections due to Mycobacterium bovis Bacillus Calmette-Guérin (BCG) are unusual and occur mostly in patients with inborn error of immunity (IEI) or acquired immunodeficiency. However, cases of secondary BCGosis due to intravesical BCG instillation have been described. Herein, we present a case of severe BCGosis occurring in an unusual situation.

Case description: We report one case of severe disseminated BCG disease occurring after hematological malignancy in a 48-year-old man without BCG instillation and previously vaccinated in infancy with no complication. Laboratory investigations demonstrated that he was not affected by any known or candidate gene of IEI or intrinsic cellular defect involving IFNγ pathway. Whole genome sequencing of the BCG strain showed that it was most closely related to the M. bovis BCG Tice strain, suggesting an unexpected relationship between the secondary immunodeficiency of the patient and the acquired BCG infection.

Conclusion: This case highlights the fact that, in addition to the IEI, physicians, as well as microbiologists and pharmacists should be aware of possible acquired disseminated BCG disease in secondary immunocompromised patients treated in centers that administrate BCG for bladder cancers.

Keywords: BCG; BCGosis-susceptible PIDs; Immunodeficiency; case report; contamination; hematological malignancies.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravesical
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antitubercular Agents / therapeutic use
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / adverse effects
  • Hematologic Neoplasms / drug therapy*
  • Host-Pathogen Interactions
  • Humans
  • Immune Reconstitution*
  • Immunocompromised Host*
  • Male
  • Middle Aged
  • Mycobacterium bovis / drug effects
  • Mycobacterium bovis / immunology
  • Mycobacterium bovis / pathogenicity*
  • Opportunistic Infections / drug therapy
  • Opportunistic Infections / immunology
  • Opportunistic Infections / microbiology*
  • Risk Factors
  • Treatment Outcome
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / immunology
  • Tuberculosis, Pulmonary / microbiology*
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / immunology

Substances

  • Antitubercular Agents
  • BCG Vaccine